Streamline Health Solns Azioni (NASDAQ: STRM)

Ultime notizie per Streamline Health Solns (NASDAQ:STRM) Azioni

Streamline Health Solns

Streamline Health Solutions Inc provides transformational data-driven solutions for healthcare organizations. It provides computer software-based solutions through its looking glass platform. Its solutions include coding and CDI, coding audit, and financial management solutions. It offers various services, such as custom integration services, training services, electronic image conversion and database monitoring services. It sells its solutions and services in North America to hospitals and health systems, including physician practices, through its direct sales force and its reseller partnerships.

Earnings

News

STRM

Streamline Health Solns Q1 EPS $(0.40) Up From $(0.75) YoY, Sales $4.81M Up From $4.33M YoY

U.S. stocks traded mostly higher midway through trading, with the S&amp;P 500 gaining around 0.4% on Thursday.
The Dow traded up 0.03% to 42,113.07 while the NASDAQ jumped 0.59% to 19,213.22. The S&amp;P 500 also rose, gaining, 0.37% to 5,910.10.
Check This Out: <a href="https://www.benzinga.com/25/05/45640155/wall-streets-most-accurate-analysts-give-their-take-on-3-materials-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Materials Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Real estate shares jumped by 0.9% on Thursday.
In trading on Thursday, communication services stocks fell by 0.5%.
Top Headline
Best Buy Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) posted downbeat results for the first quarter.
The company's first-quarter sales fell around 1% (comparable sales fell 0.7%) year over year to $8.77 billion. It missed the analyst consensus estimate of $9.22 billion. Best Buy reported adjusted earnings of $1.15, missing the consensus of $1.31.
Best Buy lowered its fiscal 2026 adjusted earnings from $6.20-$6.60 per share to $6.15-$6.30 per share versus consensus of $6.13 per share. The company lowered its sales guidance from $41.4 billion to $42.2 billion to $41.1 billion to $41.9 billion. The consensus hovers around $41.44 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Alzamend Neuro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) shares shot up 99% to $6.60 after the company dosed the first patient in its Phase II clinical trial of AL001.</li>
<li>Shares of Streamline Health Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) got a boost, surging 128% to $5.07 after the company announced MDaudit will acquire the company for $5.34 per share in cash.</li>
<li>ORIC Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>) shares were also up, gaining 25% to $7.45 after the company announced preliminary efficacy and safety data from its ongoing Phase 1b trial of ORIC-944. Additionally, the company announced a $125 million private placement, which was priced at an 18% premium to its 10-day trailing volume-weighted average price.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Eos Energy Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) shares dropped 19% to $4.8650 after the company announced a $75 million common stock offering and a $175 million convertible senior notes offering.</li>
<li>Shares of Caleres, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAL#NYSE">CAL</a>) were down 14% to $14.16 after the company reported first-quarter financial results and missed its adjusted EPS and sales estimates. Additionally, the company announced it will suspend its guidance.</li>
<li>Revelation Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) was down, falling 50% to $0.9651 after the company announced a $4 million public offering.</li>
</ul>
Commodities In commodity news, oil traded down 1.3% to $61.03 while gold traded up 1.4% at $3,341.80.
Silver traded up 0.3% to $33.255 on Thursday, while copper rose 0.2% to $4.6820.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.09%, while Spain's IBEX 35 Index rose 0.21%. London's FTSE 100 rose 0.01%, Germany's DAX 40 fell 0.24% and France's CAC 40 gained 0.15% during the session.
Asia Pacific Markets
Asian markets closed higher on Thursday, with Japan's Nikkei gaining 1.88%, Hong Kong's Hang Seng Index rising 1.35%, China's Shanghai Composite Index rising 0.70% and India's BSE Sensex rising 0.39%.
Economics
<ul class="wp-block-list">
<li>U.S. initial jobless claims rose by 14,000 from the previous week to 240,000 in the week ending May 24th, compared to market estimates of 230,000.</li>
<li>The U.S. economy shrank at an annualized rate of 0.2% in the first quarter, compared to the initial estimate of a 0.3% decline.</li>
<li>Pending home sales in the U.S. fell 6.3% from the previous month in April.</li>
<li>U.S. crude oil inventories declined by 2.795 million barrels in the week ended May 23, compared to market estimates of a 0.6 million barrel rise.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/25/05/45667868/top-2-materials-stocks-that-are-ticking-portfolio-bombs">Top 2 Materials Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Markets

Trading Ideas

ALZN

EOSE

ORIC

REVB

Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results

<h3>Gainers</h3>
<ul>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) stock moved upwards by 125.2% to $5.16 during Thursday's regular session. The company's market cap stands at $22.0 million. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares increased by 115.65% to $0.61. The market value of their outstanding shares is at $27.1 million. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) shares increased by 86.29% to $6.18. The company's market cap stands at $4.5 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares rose 64.65% to $0.01. The market value of their outstanding shares is at $3.9 million. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) shares moved upwards by 55.53% to $1.39. The company's market cap stands at $19.9 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 54.8% to $805.0. The market value of their outstanding shares is at $10.4 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) stock declined by 54.6% to $0.88 during Thursday's regular session. </li>
<li>Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) shares decreased by 28.59% to $0.65. The company's market cap stands at $62.2 million. </li>
<li>Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) stock decreased by 26.25% to $7.12. The market value of their outstanding shares is at $738.0 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock declined by 24.96% to $4.39. The company's market cap stands at $119.8 million. </li>
<li>EXoZymes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXOZ#NASDAQ">EXOZ</a>) stock decreased by 21.58% to $10.98. The company's market cap stands at $91.8 million. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) shares fell 16.91% to $0.59. The company's market cap stands at $29.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ASBP

BSGM

EXOZ

HBIO

HCTI

IMUX

MODV

NTLA

12 Health Care Stocks Moving In Thursday's Intraday Session

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 1% on Thursday.
Following the market opening Thursday, the Dow traded up 0.17% to 42,170.51 while the NASDAQ jumped 1.16% to 19,322.40. The S&amp;P 500 also rose, gaining, 0.69% to 5,929.30.
Check This Out: <a href="https://www.benzinga.com/25/05/45640155/wall-streets-most-accurate-analysts-give-their-take-on-3-materials-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Materials Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Information technology shares jumped by 1.5% on Thursday.
In trading on Thursday, consumer staples stocks fell by 0.2%.
Top Headline
NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) reported better-than-expected revenue for the first quarter.
The company posted first-quarter revenue of $44.1 billion, up 69% year-over-year and up 12% from the fourth quarter. The revenue beat a Street consensus estimate of $43.2 billion. Nvidia reported adjusted earnings of 81 cents per share in the first quarter. Nvidia said it sees second-quarter revenue of $45.0 billion, +/- 2%. The guidance includes the loss of $8.0 billion in H20 revenue due to the export controls.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Alzamend Neuro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) shares shot up 140% to $7.95 after the company dosed the first patient in its Phase II clinical trial of AL001.</li>
<li>Shares of Streamline Health Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) got a boost, surging 123% to $4.9525 after the company announced MDaudit will acquire the company for $5.34 per share in cash.</li>
<li>Healthcare Triangle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares were also up, gaining 105% to $0.0119.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Elong Power Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELPW#NASDAQ">ELPW</a>) shares dropped 62% to $1.31.</li>
<li>Shares of Brooge Energy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BROG#NASDAQ">BROG</a>) were down 58% to $1.7699. Brooge Energy announced voluntarily delisting from the Nasdaq.</li>
<li>Revelation Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) was down, falling 52% to $0.9394 after the company announced a $4 million public offering.</li>
</ul>
Commodities In commodity news, oil traded down 1.1% to $61.17 while gold traded up 1.4% at $3,339.40.
Silver traded up 0.6% to $33.355 on Thursday, while copper rose 0.9% to $4.7170.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.1%, while Spain's IBEX 35 Index rose 0.2%. London's FTSE 100 fell 0.1%, Germany's DAX 40 fell 0.2% and France's CAC 40 gained 0.2% during the session.
Asia Pacific Markets
Asian markets closed higher on Thursday, with Japan's Nikkei gaining 1.88%, Hong Kong's Hang Seng Index rising 1.35%, China's Shanghai Composite Index rising 0.70% and India's BSE Sensex rising 0.39%.
Economics
<ul class="wp-block-list">
<li>U.S. initial jobless claims rose by 14,000 from the previous week to 240,000 in the week ending May 24th, compared to market estimates of 230,000.</li>
<li>The U.S. economy shrank at an annualized rate of 0.2% in the first quarter, compared to the initial estimate of a 0.3% decline.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45667868/top-2-materials-stocks-that-are-ticking-portfolio-bombs">Top 2 Materials Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

BROG

ELPW

NVDA

Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue

WIIM

Sreamline Health Solutions shares are trading higher after the company announced MDaudit will acquire the company for $5.34 per share in cash.

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

MDaudit To Acquire All Outstanding Shares Of Streamline Stock For $5.34 Per Share In Cash

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) reported quarterly losses of $(0.42) per share. This is a 40 percent decrease over losses of $(0.30) per share from the same period last year. The company reported $4.68 million in sales this quarter. This is a 12.78 percent decrease over sales of $5.36 million the same period last year.

Streamline Health Solns Q4 EPS $(0.42) Down From $(0.30) YoY, Sales $4.68M Down From $5.36M YoY

Contracts

Streamline Health Announces New eValuator Contract With Ohio-Based Health System; Terms Not Disclosed

<h3>Gainers</h3>
<ul>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares rose 187.3% to $0.75 during Tuesday's pre-market session. The company's market cap stands at $11.6 million. The company's, Q4 earnings came out yesterday. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares moved upwards by 137.3% to $0.86. The market value of their outstanding shares is at $2.8 million. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares moved upwards by 42.46% to $67.0. The company's market cap stands at $364.2 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) stock increased by 27.1% to $2.43. The market value of their outstanding shares is at $64.3 million. As per the press release, Q4 earnings came out 3 days ago. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares moved upwards by 25.08% to $0.04. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares moved upwards by 24.13% to $1.08. The market value of their outstanding shares is at $12.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) stock declined by 52.7% to $1.4 during Tuesday's pre-market session. The company's market cap stands at $109.6 million. </li>
<li>InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) shares decreased by 19.13% to $2.41. The market value of their outstanding shares is at $325.9 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares fell 18.22% to $2.29. The market value of their outstanding shares is at $9.7 million. </li>
<li>OncoCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCX#NASDAQ">OCX</a>) shares decreased by 17.98% to $2.51. The market value of their outstanding shares is at $71.7 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares declined by 17.84% to $0.76. The company's market cap stands at $54.6 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock fell 9.14% to $0.36. The market value of their outstanding shares is at $9.0 million. As per the news, the Q4 earnings report came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIAF

CTOR

GANX

INNV

NUTX

PHLT

RSLS

SNSE

STSS

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Streamline Health Signed A New Contract For The Use Of RevID With A 120-bed, Oracle Health-ehr Based Health System With Facilities In Kentucky

Streamline Health Signs New Contract For Use Of eValuator With Deaconess Health System

Streamline Health Solutions Announced That It Has Signed A New Contract For The Use Of RevID With A 400-bed, Oracle Health-EHR Based Health System With Facilities In Western Texas

Due to the continued unpredictability of timing related to the closing of new contracts, the Company has not provided more specific guidance related to the timing of bookings.

Guidance

Streamline Health Reiterates $15.5M Implemented SaaS ARR Adjusted EBITDA Breakeven Run Rate Expectation; Accelerates Expectation For Achievement The Goal To H1 Of FY25

Streamline Health Q3 EPS $(0.61) Up From $(3.15) YoY, Sales $4.42M Down From $6.13M YoY

<h3>Companies Reporting Before The Bell</h3>
• Zedge (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZDGE#AMEX">ZDGE</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $7.28 million. 
<h3>Companies Reporting After The Bell</h3>
• Quipt Home Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QIPT#NASDAQ">QIPT</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $65.75 million. 
• Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $5.31 million. 
• Red Cat Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) is expected to report quarterly loss at $0.09 per share on revenue of $4.13 million. 
• Mitek Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITK#NASDAQ">MITK</a>) is expected to report quarterly earnings at $0.17 per share on revenue of $41.30 million. 
• RCI Hospitality Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RICK#NASDAQ">RICK</a>) is projected to report quarterly earnings at $0.37 per share on revenue of $72.98 million. 
• Ark Restaurants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARKR#NASDAQ">ARKR</a>) is estimated to report earnings for its fourth quarter. 
• Mama`s Creations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMA#NASDAQ">MAMA</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $30.05 million. 
• Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) is likely to report quarterly loss at $0.52 per share on revenue of $208.68 million. 
• Ocean Power Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#AMEX">OPTT</a>) is projected to report earnings for its second quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARKR

MAMA

MITK

OPTT

QIPT

RCAT

RICK

ZDGE

Earnings Scheduled For December 16, 2024

Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) is preparing to release its quarterly earnings on Monday, 2024-12-16. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Streamline Health Solns to report an earnings per share (EPS) of $-0.03.
Streamline Health Solns bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.15, leading to a 48.39% drop in the share price on the subsequent day.
Here's a look at Streamline Health Solns's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.60</td>
<td>-0.60</td>
<td>-0.6</td>
<td>-0.6</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.75</td>
<td>-0.75</td>
<td>-0.3</td>
<td>-0.3</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-48.0%</td>
<td>-20.0%</td>
<td>-4.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1734098458_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Streamline Health Solns were trading at $3.42 as of December 10. Over the last 52-week period, shares are down 35.59%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/STRM/earnings">To track all earnings releases for Streamline Health Solns visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Streamline Health Solns

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock rose 110.0% to $4.41 during Monday's pre-market session. The company's market cap stands at $3.6 million. </li>
<li>Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) stock rose 34.05% to $2.48. The market value of their outstanding shares is at $92.8 million. </li>
<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) shares increased by 25.17% to $1.84. The company's market cap stands at $148.9 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) shares increased by 20.82% to $14.39. The company's market cap stands at $118.7 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares moved upwards by 16.71% to $3.77. The market value of their outstanding shares is at $15.9 million. </li>
<li>Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) shares increased by 14.22% to $8.94. The company's market cap stands at $470.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) stock decreased by 72.1% to $5.6 during Monday's pre-market session. The company's market cap stands at $200.7 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 51.33% to $1.65. The company's market cap stands at $2.6 million. </li>
<li>Radiopharm Theranostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) shares fell 40.22% to $11.3. The company's market cap stands at $24.5 billion. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares decreased by 20.69% to $3.03. The company's market cap stands at $317.8 million. </li>
<li>Invizyne Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZTC#NASDAQ">IZTC</a>) shares fell 18.36% to $10.81. The market value of their outstanding shares is at $103.0 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 16.46% to $1.98. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIOA

CRVO

IPHA

IZTC

RADX

RVNC

SONN

12 Health Care Stocks Moving In Monday's Pre-Market Session

Streamline Health Solutions shares are trading higher after the company announced it signed a new contract.

Press Releases

Streamline Health® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results

MDaudit and Streamline Health Announce Definitive Merger Agreement

STRM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Streamline Health Solutions, Inc. Is Fair to Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, STRM, ATAI, STR on Behalf of Shareholders

STREAMLINE HEALTH INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Streamline Health Solutions, Inc. - STRM

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VIGL, STR, BPMC, STRM on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FLS, STR, AVDX, STRM on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STR, GTLS, STRM, SGN on Behalf of Shareholders

Streamline Health® Reports Fiscal First Quarter 2025 Financial Results

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: TASK, VIGL, STRM, and CHTR

Comments

Streamline Health Solns

Notizie

Ultime notizie per Streamline Health Solns (NASDAQ:STRM) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO